Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-995-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees23
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How were Aileron Therapeutics' earnings last quarter?
Aileron Therapeutics Inc (NASDAQ:ALRN) announced its earnings results on Tuesday, August, 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.04. View Aileron Therapeutics' Earnings History.
When is Aileron Therapeutics' next earnings date?
What price target have analysts set for ALRN?
2 equities research analysts have issued 12 month price objectives for Aileron Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Aileron Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 255.0% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.
What is the consensus analysts' recommendation for Aileron Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.
Has Aileron Therapeutics been receiving favorable news coverage?
Media coverage about ALRN stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aileron Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the next few days.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include Vernalis (VNLPY), Neos Therapeutics (NEOS), DURECT (DRRX), Processa Pharmaceuticals (PCSA), Zafgen (ZFGN), OASMIA PHARMACE/ADR (OASM), Catabasis Pharmaceuticals (CATB), Sesen Bio (SESN), Fortress Biotech (FBIO), Adamis Pharmaceuticals (ADMP), Cumberland Pharmaceuticals (CPIX), Nemus Bioscience (NMUS), Infinity Pharmaceuticals (INFI), Tiziana Life Sciences (TLSA) and VERONA PHARMA P/S (VRNA).
What other stocks do shareholders of Aileron Therapeutics own?
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
- Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 60)
- Mr. Richard J. Wanstall, VP of Fin. & Operations
- Dr. D. Allen Annis, Sr. VP of Research
- Dr. Vojislav Vukovic, Chief Medical Officer
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
How do I buy shares of Aileron Therapeutics?
Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of ALRN stock can currently be purchased for approximately $1.69.
How big of a company is Aileron Therapeutics?
Aileron Therapeutics has a market capitalization of $25.15 million. The company earns $-31,550,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.
What is Aileron Therapeutics' official website?
How can I contact Aileron Therapeutics?
Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]
MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
